What's Hot
View all perspectives
Richard Conway RichardPAConway
2 years 5 months ago
Karpouzas et al. ORAL Surveillance analysis. MACE, VTE, infections higher in those with acute and cumulative disease activity as measured by CDAI. @RheumNow #EULAR2022 POS0519 https://t.co/CtlISf2rxr
Janet Pope Janetbirdope
2 years 5 months ago
#SLE Pts vaccinated against #COVID don’t have an ⬆️risk of flare and it works and all pts should be vaccinated: K Hyrich @eular_org #EULAR2022 @RheumNow session: Types if vaccine and how they work. https://t.co/Dkl8mTQpkj
Md Yuzaiful Md Yusof Yuz6Yusof
2 years 5 months ago
#EULAR2022 Prof Pascual gave a great talks on use of transcriptomic analysis in stratifying #lupus & disease understanding. Tour de force from blood IFN signature use to Plasmablast (correlate with activity inc. in African) and Neutrophil/myeloid signatures (nephritis) @RheumNow https://t.co/tiX55ARDvC
Richard Conway RichardPAConway
2 years 5 months ago
Rojas-Gimenez et al After adjusting for age, smoking, ACPA. Male sex (OR 4.2) and longer time of having RA (OR 1.08) associated with ILD @RheumNow #EULAR2022 POS0619 https://t.co/kzG76Qwe52
Aurelie Najm AurelieRheumo
2 years 5 months ago
Does MTX have an impact on UST-immunogenicity in PsA?
Post-hoc analysis from UST RCT in 110+ pts
No difference in ADA rates & concentrations between
MTX and non-MTX groups and
ADA not associated w/ decreased UST levels
POS0079 @RheumNow #EULAR2022 https://t.co/TA0YTx8qRT
TheDaoIndex KDAO2011
2 years 5 months ago
Don’t forget about the benefits of vaccines for diseases other than #COVID19 – Dr. K Hyrich #EULAR2022 @rheumnow https://t.co/86e93ugoBQ
Eric Dein ericdeinmd
2 years 5 months ago
Pneumonia and influenza risk higher in patients with rheumatic disease!
Influenza Relative Risk: 1.2-3.3
Pneumonia RR: shown to be up to 14.2 in SLE!
💉Vaccinations work!
#EULAR2022 @Rheumnow @rheum_covid https://t.co/gvD1PaLQRe
Richard Conway RichardPAConway
2 years 5 months ago
Sanchez-Martin et al. Tocilizumab in newly diagnosed vs refractory GCA. 471 patients. Appears of relatively similar efficacy in both groups. Surprising that the difference is not greater given refractory GCA inherently more complex @RheumNow #EULAR2022 POS0817 https://t.co/HEWzYCz9YD
TheDaoIndex KDAO2011
2 years 5 months ago
Proof that vaccines work in our rheum patients; reduction in hospitalization, ICUs, death – Dr. K Hyrich #EULAR2022 @rheumnow https://t.co/u8PWvgfdiC
Eric Dein ericdeinmd
2 years 5 months ago
#EULAR2022:
Kimme Hyrich: Think about Herpes zoster risk in ALL rheumatic disease patients (not just, but particularly with JAKs).
💉Avoid Zostavax (Live) in patients on immunosuppression
💉Warn side effects are common with Shingrix
@RheumNow @rheum_covid https://t.co/w7p4oHuqL9
Richard Conway RichardPAConway
2 years 5 months ago
2 year guselkumab data from Discover-2 @DrLauraCoates et al. Continue incremental improvements across all key domains through 2 years of treatment @RheumNow #EULAR2022 POS1017 https://t.co/wcSKCID9Yt
Aurelie Najm AurelieRheumo
2 years 5 months ago
☄️ Biomarkers substudies of COSMOS & DISCOVER-1 RCT GUS in PsA:
TNFi-IR pts have a different plasma signature w/ higher BL IL-22 & TNF
*Association between BL IL-22 levels & W24 PASI75
and trend for BL IL-22 levels & W24 ACR20
#EULAR2022 @RheumNow POS0074 @StefanSiebert1 https://t.co/Midtug4NJO
TheDaoIndex KDAO2011
2 years 5 months ago
Dr. K Hyrich who/when to vaccinate. #EULAR2022 @rheumnow https://t.co/40y9ngJnbW
TheDaoIndex KDAO2011
2 years 5 months ago
#Vaccine disparities globally #EULAR2022 @rheumnow https://t.co/w12ok1Y1b5
Eric Dein ericdeinmd
2 years 5 months ago
Kimme Hydrich: There is no increased of "exceedingly rare" vaccination adverse effects in rheumatic patients
💉APLS is NOT a risk factor for thrombotic AEs with vaccination
#EULAR2022 @Rheumnow @rheum_covid
Poster Hall